Tinnitus - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Tinnitus - Pipeline Review, H2 2016

Tinnitus - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Tinnitus - Pipeline Review, H2 2016
Published Sep 14, 2016
62 pages — Published Sep 14, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tinnitus - Pipeline Review, H2 2016, provides an overview of the Tinnitus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tinnitus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tinnitus
- The report reviews pipeline therapeutics for Tinnitus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Tinnitus therapeutics and enlists all their major and minor projects
- The report assesses Tinnitus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Tinnitus


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Tinnitus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by i

  
Source:
Document ID
GMDHC8447IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Tinnitus Overview71
Therapeutics Development82
  Pipeline Products for Tinnitus Overview81
  Pipeline Products for Tinnitus Comparative Analysis91
Tinnitus Therapeutics under Development by Companies101
Tinnitus Therapeutics under Investigation by Universities/Institutes111
Tinnitus Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Tinnitus Products under Development by Companies151
Tinnitus Products under Investigation by Universities/Institutes161
Tinnitus Companies Involved in Therapeutics Development177
  AudioCure Pharma GmbH171
  Auris Medical Holding AG181
  Knopp Biosciences LLC191
  Merz Pharma GmbH &Co. KgaA201
  Otonomy, Inc.211
  SciFluor Life Sciences, LLC221
  Sound Pharmaceuticals, Inc.231
Tinnitus Therapeutics Assessment248
  Assessment by Monotherapy Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration292
  Assessment by Molecule Type311
Drug Profiles3220
  AM-102 Drug Profile321
  AUT-3 Drug Profile331
  Drug to Activate KCNQ for Tinnitus Drug Profile341
  esketamine hydrochloride Drug Profile355
  gacyclidine SR Drug Profile402
  neramexane mesylate Drug Profile422
  SF-0034 Drug Profile442
  Small Molecules for Tinnitus Drug Profile461
  Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus Drug Profile471
  Small Molecules to Inhibit TNF-Alpha for Tinnitus Drug Profile481
  SPI-1005 Drug Profile492
  SPI-3005 Drug Profile511
Tinnitus Dormant Projects521
Tinnitus Product Development Milestones538
  Featured News &Press Releases531
    Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus531
    Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million531
    Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus541
    Jun 28, 2016: Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute Inner Ear Tinnitus541
    Jun 14, 2016: Auris Medical Hosts Key Opinion Leader Event Focused on Phase 3 Program for Acute Inner Ear Tinnitus551
    Jun 07, 2016: Auris Medical to Host Key Opinion Leader Event Focused on Acute Inner Ear Tinnitus and AM-101 Phase 3 Program on June 14 in New York City551
    Mar 30, 2016: Auris Medical Completes Enrollment of TACTT2 Phase 3 Trial of AM-101 in Acute Inner Ear Tinnitus561
    Nov 16, 2015: Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311561
    Oct 05, 2015: Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311561
    Jul 02, 2015: Auris Medical Holding Provides Update on U.S. Intellectual Property Portfolio571
    Jun 19, 2015: SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience571
    Apr 20, 2015: Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals581
    Mar 13, 2015: Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus591
    Mar 11, 2015: Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City591
    Mar 10, 2015: Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101592
Appendix612
  Methodology611
  Coverage611
  Secondary Research611
  Primary Research611
  Expert Panel Validation611
  Contact Us611
  Disclaimer621

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tinnitus - Pipeline Review, H2 2016" Sep 14, 2016. Alacra Store. May 11, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tinnitus-Pipeline-Review-H2-2016-2088-16532>
  
APA:
Global Markets Direct - Market Research. (2016). Tinnitus - Pipeline Review, H2 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved May 11, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tinnitus-Pipeline-Review-H2-2016-2088-16532>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.